| Agent |
Route |
Dosing |
Indication |
| TNF Inhibitors (MID Etanercept |
sq |
50 mg weekly |
Moderate to severe RA |
| Infliximah |
iv |
3 mg/kg at 0.2.6 necks, then every ft weeks thereafter: dose may be Increased to 10 mg/kg: Interval may be decreased to every • weeks. Administer with tnethOtrexate. |
DMARD naive RA Moderate to severe RA DMARD naive RA |
| Adalimumab |
sq |
40mg every other week: Interval can be decreased to every week |
Moderate to severe RA DMARD naive RA |
| Golimurnab |
Sri |
50 mg every month |
Moderate to severe RA DMARD naive RA |
| Certobzumabpegol |
sq |
400 mg at 2.4 weeks then 200 mg every 2 weeks thereafter. 400 mg every 4 weeks is an alternative (or maintenance. |
Moderate to severe RA OMARD naive RA |
| Other approved biologics |
|
|
|
| Ritaximab |
Iv |
1000Ing at 0. 15 days then based on clinical symptoms (not more frequently than every 16 weeks) |
Moderate to severe RA. after failure of TNF antagonist |
| Abatacept |
Iv/sq |
Iv route: Weight based (<601r4:500mg. 60-100Kg: 750mg. >100KR:1000mg) at 0.2.4 weeks and then every
• weeks thereafter. SQ route: 125 mg weekly following
• Single Iv Manion ( lOms/ks) |
Moderate to severe RA DMARD naive RA |
| Tocilizumals |
iv |
Draggles event 4 weeks. May be Increased to 8 mg/lCg (not to exceed 800rng per infusion). |
Moderate to severe RA. after failure & TNF antagonist |
| Investigational Drugs |
|
Mechanism of Action |
Completed study stage |
| CP-690.550 (tofacitinib) |
PO |
AK 3 Inhibition |
Phase II |
| R788 ((ostamatinib) |
PO |
Syk Inhibition |
Phase II |
| Atacicept |
iv |
Anti- IlLyS/APSUL |
Phase II |
| AIN457 |
iv |
IL-17 inhibition |
Phase I/11 |
| LY243962I |
|
|
|
| Orselizumab |
iv |
Anti-CD20 Monoclonal Antibodies |
Phase III |
| Ofatumumab |
|
|
Phase 1/11 |
| Apilimodmesylate (STA-5326) |
PO |
1L-12/11-23 Inhibition |
Phase 11 trials |
| Parnapimod VX-702 |
PO |
P38 MARK Inhibition |
Phase II |
